These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 9125443)

  • 1. Systemic administration of rotenone produces selective damage in the striatum and globus pallidus, but not in the substantia nigra.
    Ferrante RJ; Schulz JB; Kowall NW; Beal MF
    Brain Res; 1997 Apr; 753(1):157-62. PubMed ID: 9125443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mitochondrial complex inhibitors preferentially damage substantia nigra dopamine neurons in rat brain slices.
    Bywood PT; Johnson SM
    Exp Neurol; 2003 Jan; 179(1):47-59. PubMed ID: 12504867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation.
    Sherer TB; Kim JH; Betarbet R; Greenamyre JT
    Exp Neurol; 2003 Jan; 179(1):9-16. PubMed ID: 12504863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic low-dose melatonin treatment maintains nigrostriatal integrity in an intrastriatal rotenone model of Parkinson's disease.
    Carriere CH; Kang NH; Niles LP
    Brain Res; 2016 Feb; 1633():115-125. PubMed ID: 26740407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rotenone induced neurotoxicity in rat brain areas: a histopathological study.
    Swarnkar S; Singh S; Sharma S; Mathur R; Patro IK; Nath C
    Neurosci Lett; 2011 Sep; 501(3):123-7. PubMed ID: 21435374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic inhalation of rotenone or paraquat does not induce Parkinson's disease symptoms in mice or rats.
    Rojo AI; Cavada C; de Sagarra MR; Cuadrado A
    Exp Neurol; 2007 Nov; 208(1):120-6. PubMed ID: 17880941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroprotection by valproic acid in an intrastriatal rotenone model of Parkinson's disease.
    Carriere CH; Kang NH; Niles LP
    Neuroscience; 2014 May; 267():114-21. PubMed ID: 24613722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rats with unilateral median forebrain bundle, but not striatal or nigral, lesions by the neurotoxins MPP+ or rotenone display differential sensitivity to amphetamine and apomorphine.
    Sindhu KM; Banerjee R; Senthilkumar KS; Saravanan KS; Raju BC; Rao JM; Mohanakumar KP
    Pharmacol Biochem Behav; 2006 Jun; 84(2):321-9. PubMed ID: 16820197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rotenone, deguelin, their metabolites, and the rat model of Parkinson's disease.
    Caboni P; Sherer TB; Zhang N; Taylor G; Na HM; Greenamyre JT; Casida JE
    Chem Res Toxicol; 2004 Nov; 17(11):1540-8. PubMed ID: 15540952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of nitric oxide in rotenone-induced nigro-striatal injury.
    He Y; Imam SZ; Dong Z; Jankovic J; Ali SF; Appel SH; Le W
    J Neurochem; 2003 Sep; 86(6):1338-45. PubMed ID: 12950443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic systemic complex I inhibition induces a hypokinetic multisystem degeneration in rats.
    Höglinger GU; Féger J; Prigent A; Michel PP; Parain K; Champy P; Ruberg M; Oertel WH; Hirsch EC
    J Neurochem; 2003 Feb; 84(3):491-502. PubMed ID: 12558969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bilateral upregulation of α-synuclein expression in the mouse substantia nigra by intracranial rotenone treatment.
    Carriere CH; Kang NH; Niles LP
    Exp Toxicol Pathol; 2017 Feb; 69(2):109-114. PubMed ID: 27986376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of L-thyroxin in counteracting rotenone induced neurotoxicity in rats.
    Salama M; Helmy B; El-Gamal M; Reda A; Ellaithy A; Tantawy D; Mohamed M; El-Gamal A; Sheashaa H; Sobh M
    Environ Toxicol Pharmacol; 2013 Mar; 35(2):270-7. PubMed ID: 23357603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rotenone increases glutamate-induced dopamine release but does not affect hydroxyl-free radical formation in rat striatum.
    Leng A; Feldon J; Ferger B
    Synapse; 2003 Dec; 50(3):240-50. PubMed ID: 14515342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute intranigral infusion of rotenone in rats causes progressive biochemical lesions in the striatum similar to Parkinson's disease.
    Saravanan KS; Sindhu KM; Mohanakumar KP
    Brain Res; 2005 Jul; 1049(2):147-55. PubMed ID: 15936733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The behavioural and neuropathological impact of intranigral AAV-α-synuclein is exacerbated by systemic infusion of the Parkinson's disease-associated pesticide, rotenone, in rats.
    Mulcahy P; O'Doherty A; Paucard A; O'Brien T; Kirik D; Dowd E
    Behav Brain Res; 2013 Apr; 243():6-15. PubMed ID: 23295396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sodium salicylate protects against rotenone-induced parkinsonism in rats.
    Madathil SK; Karuppagounder SS; Mohanakumar KP
    Synapse; 2013 Aug; 67(8):502-14. PubMed ID: 23447126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Iron concentration reduced in ventral pallidum, globus pallidus, and substantia nigra by GABA-transaminase inhibitor, gamma-vinyl GABA.
    Hill JM
    Brain Res; 1985 Sep; 342(1):18-25. PubMed ID: 4041811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease.
    Jenner P; Marsden CD
    J Neural Transm Suppl; 1986; 20():11-39. PubMed ID: 3091760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential role of GABAA and GABAB receptors in two distinct output stations of the rat striatum: studies on the substantia nigra pars reticulata and the globus pallidus.
    Ikeda H; Kotani A; Koshikawa N; Cools AR
    Neuroscience; 2010 Apr; 167(1):31-9. PubMed ID: 20132872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.